Fontan患者房室瓣功能的长期随访:房室瓣手术的影响
该研究分析了113例Fontan术后单心室患者的长期随访资料,评估房室瓣与心室功能的关系及房室瓣手术的影响。中位随访16.3年,无移植生存率在10-25年为96.1±1.9%和90.4±5.8%,12.4%患者需房室瓣手术,瓣膜功能随时间缓慢恶化。
要点
- 中位随访16.3年,Fontan术后10-25年无移植生存率为96.1±1.9%和90.4±5.8%。
- 14例(12.4%)需房室瓣手术,瓣膜功能随时间恶化(HR 1.112)。
- 左心室优势者心室功能恶化较慢(HR 0.927),房室瓣术后心室功能恶化更明显(HR 1.103)。
核心结论
- 在均一治疗的Fontan人群中,25年无移植生存率令人鼓舞。
- 12.4%患者需房室瓣手术,多数获得持久瓣膜功能。
- 房室瓣和心室功能随时间缓慢下降令人担忧,提示可能需要额外的心力衰竭治疗。
研究设计与样本
- 分析Fontan术后单心室患者的无移植生存和房室瓣手术需求,并进行长期瓣膜和心室功能的纵向超声心动图检查。
- 共纳入113例完成Fontan的患者,右单心室形态33.6%,左心室形态62.8%,不定型3.6%。
- 围手术期死亡2.7%(n=3)。
主要发现
- 中位随访16.3年(四分位距10.6-23.6),无移植生存率在10-25年为96.1±1.9%和90.4±5.8%。
- 14例(12.4%)儿童共接受20次房室瓣手术,其中Fontan术前10次、Fontan术中8次、Fontan术后2次;房室瓣手术累积发生率在1-5年为5.7±2.2%和12.3±3.2%。
- 房室瓣功能随时间恶化(HR 1.112,95%CI 1.089-1.138,P<0.001),瓣膜形态(P=0.736)或心室优势(P=0.484)间无差异。
- 需房室瓣手术者房室瓣功能障碍更严重(HR 20.383,95%CI 6.223-36.762,P<0.001),但修复后演变与未手术者相当(HR 1.070,95%CI 0.987-1.160,P=0.099)。
- 心室功能随时间进展性恶化(HR 1.141,95%CI 1.097-1.182,P<0.001),左心室优势者恶化显著较少(HR 0.927,95%CI 0.860-0.999,P=0.047),房室瓣术后恶化更明显(HR 1.103,95%CI 1.014-1.167,P=0.022)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to evaluate the relationship between atrioventricular valve and ventricular function in Fontan survivors, including the effect of atrioventricular valve surgery. METHODS: Analysis focused on transplant-free survival and the need for atrioventricular valve surgery in single ventricle patients after Fontan completion. Longitudinal echocardiographic examination of long-term valve and ventricular function was performed. RESULTS: Fontan completion was performed in 113 patients, having a right univentricular morphology in 33.6%, a left ventricle morphology in 62.8% and ambiguous in 3.6%. Perioperative mortality was 2.7% (n = 3). Within a median follow-up of 16.3 years (interquartile range 10.6-23.6), transplant-free survival was 96.1 ± 1.9% and 90.4 ± 5.8% at 10-25 years. Twenty AV valve procedures were performed in 14 (12.4%) children, respectively, pre-Fontan (n = 10), per-Fontan (n = 8) and post-Fontan (n = 2), resulting in a cumulative incidence of AV valve surgery is 5.7 ± 2.2% and 12.3 ± 3.2% at 1-5 years. Atrio-ventricular valve function deteriorated over time [hazard ratio (HR) 1.112, 95% confidence interval (CI) 1.089-1.138, P < 0.001], without difference for valve morphology (P = 0.736) or ventricular dominance (P = 0.484). AV valve dysfunction was greater in patients requiring AV valve surgery (HR 20.383, 95% CI 6.223-36.762, P < 0.001) but showed a comparable evolution since repair to those without valve surgery (HR 1.070, 95% CI 0.987-1.160, P = 0.099). Progressive time-related ventricular dysfunction was observed (HR 1.141, 95% CI 1.097-1.182, P < 0.001), significantly less in left ventricle-dominance (HR 0.927, 95% CI 0.860-0.999, P = 0.047) but more after AV valve surgery (HR 1.103, 95% CI 1.014-1.167, P = 0.022). CONCLUSIONS: In a homogeneously treated Fontan population, 25-year transplant-free survival is encouraging. Atrio-ventricular valve surgery was necessary in 12.4%, resulting mostly in a durable valve function. However, a slow time-related decline of atrioventricular valve function as of ventricular function is worrisome, evoking a role for additional heart failure therapy.
引用
- Bove T, Grootjans E, Naessens R, et al. Long-term follow-up of atrioventricular valve function in Fontan patients: effect of atrioventricular valve surgery. Eur J Cardiothorac Surg. 2023. PMID: 37682065. doi:10.1093/ejcts/ezad305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。